|
1
|
Kommoss S, du Bois A, Ridder R, Trunk MJ,
Schmidt D, Pfisterer J and Kommoss F; AGO-OVAR: Independent
prognostic significance of cell cycle regulator proteins p16(INK4a)
and pRb in advanced-stage ovarian carcinoma including optimally
debulked patients: A translational research subprotocol of a
randomised study of the arbeitsgemeinschaft gynaekologische
onkologie ovarian cancer study group. Br J Cancer. 96:306–313.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lumbroso-Le Rouic L, Aerts I, Hajage D,
Lévy-Gabriel C, Savignoni A, Algret N, Cassoux N, Bertozzi AI,
Esteve M, Doz F and Desjardins L: Conservative treatment of
retinoblastoma: A prospective phase II randomized trial of
neoadjuvant chemotherapy followed by local treatments and
chemothermotherapy. Eye (Lond). 30:46–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DeMichele A, Clark AS, Tan KS, Heitjan DF,
Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, et
al: CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced
breast cancer: Phase II activity, safety, and predictive biomarker
assessment. Clin Cancer Res. 21:995–1001. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martin J, Bryar P, Mets M, Weinstein J,
Jones A, Martin A, Vanin EF, Scholtens D, Costa FF, Soares MB and
Laurie NA: Differentially expressed miRNAs in retinoblastoma. Gene.
512:294–299. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wei Y, Sun J and Li X: MicroRNA-215
enhances invasion and migration by targeting retinoblastoma tumor
suppressor gene 1 in high-grade glioma. Biotechnol Lett.
39:197–205. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu SS, Wang YS, Sun YF, Miao LX, Wang J,
Li YS, Liu HY and Liu QL: Plasma microRNA-320, microRNA-let-7e and
microRNA-21 as novel potential biomarkers for the detection of
retinoblastoma. Biomed Rep. 2:424–428. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qi L, Zhu F, Li SH, Si LB, Hu LK and Tian
H: Retinoblastoma binding protein 2 (RBP2) promotes
HIF-1α-VEGF-induced angiogenesis of non-small cell lung cancer via
the Akt pathway. PLoS One. 9:e1060322014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xiao W, Chen X and He M: Inhibition of the
Jagged/Notch pathway inhibits retinoblastoma cell proliferation via
suppressing the PI3K/Akt, Src, p38MAPK and Wnt/β-catenin signaling
pathways. Mol Med Rep. 10:453–458. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eo SH, Kim JH and Kim SJ: Induction of
G2/M arrest by berberine via activation of PI3K/Akt and p38 in
human chondrosarcoma cell line. Oncol Res. 22:147–157. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gui F, Hong Z, You Z, Wu H and Zhang Y:
MiR-21 inhibitor suppressed the progression of retinoblastoma via
the modulation of PTEN/PI3K/AKT pathway. Cell Biol Int.
40:1294–1302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu J, Li Q, Li R, Ren P and Dong S:
MicroRNA-363-3p inhibits papillary thyroid carcinoma progression by
targeting PIK3CA. Am J Cancer Res. 7:148–158. 2017.PubMed/NCBI
|
|
12
|
Friedman DN, Lis E, Sklar CA, Oeffinger
KC, Reppucci M, Fleischut MH, Francis JH, Marr B, Abramson DH and
Dunkel IJ: Whole-body magnetic resonance imaging (WB-MRI) as
surveillance for subsequent malignancies in survivors of hereditary
retinoblastoma: A pilot study. Pediatr Blood Cancer. 61:1440–1444.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song W, Liu MG, Zhang JB, Zhang JJ, Sun MM
and Yu QK: Mechanism of action of EBV, Bcl-2, p53, c-Myc and Rb in
non-Hodgkin's lymphoma. Eur Rev Med Pharmacol Sci. 20:1093–1097.
2016.PubMed/NCBI
|
|
14
|
Singh L, Pushker N, Saini N, Sen S, Sharma
A, Bakhshi S, Chawla B and Kashyap S: Expression of pro-apoptotic
Bax and anti-apoptotic Bcl-2 proteins in human retinoblastoma. Clin
Exp Ophthalmol. 43:259–267. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
La Thangue NB: A mismatched role for
Bcl-2. Nat Cell Biol. 7:101–102. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lai JH, Fleming KE, Ly TY, Pasternak S,
Godlewski M, Doucette S and Walsh NM: Pure versus combined Merkel
cell carcinomas: Immunohistochemical evaluation of cellular
proteins (p53, Bcl-2, and c-kit) reveals significant overexpression
of p53 in combined tumors. Hum Pathol. 46:1290–1296. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang G, Cao X, Lai S, Luo X, Feng Y, Xia
X, Yen PM, Gong J and Hu J: PI3K stimulates DNA synthesis and
cell-cycle progression via its p55PIK regulatory subunit
interaction with PCNA. Mol Cancer Ther. 12:2100–2109. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tomosugi M, Sowa Y, Yasuda S, Tanaka R, te
Riele H, Ikawa H, Koyama M and Sakai T: Retinoblastoma
gene-independent G1 phase arrest by flavone, phosphatidylinositol
3-kinase inhibitor, and histone deacetylase inhibitor. Cancer Sci.
103:2139–2143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wei TY, Juan CC, Hisa JY, Su LJ, Lee YC,
Chou HY, Chen JM, Wu YC, Chiu SC, Hsu CP, et al: Protein arginine
methyltransferase 5 is a potential oncoprotein that upregulates G1
cyclins/cyclin-dependent kinases and the phosphoinositide
3-kinase/AKT signaling cascade. Cancer Sci. 103:1640–1650. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vora SR, Juric D, Kim N, Mino-Kenudson M,
Huynh T, Costa C, Lockerman EL, Pollack SF, Liu M, Li X, et al: CDK
4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K
inhibitors. Cancer Cell. 26:136–149. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Choy E, Hornicek F, MacConaill L, Harmon
D, Tariq Z, Garraway L and Duan Z: High-throughput genotyping in
osteosarcoma identifies multiple mutations in
phosphoinositide-3-kinase and other oncogenes. Cancer.
118:2905–2914. 2012. View Article : Google Scholar : PubMed/NCBI
|
